LivaNova to Present at the American Epilepsy Society 2024 Annual Meeting
LivaNova PLC (Nasdaq: LIVN), a leading medical technology firm, has announced its upcoming engagement at the American Epilepsy Society's 2024 Annual Meeting, which is set to take place from December 6 to 10. This prominent event will be an opportunity for LivaNova to highlight its innovative therapies and technologies designed for the treatment of drug-resistant epilepsy. Through a series of scientific posters, the company aims to deepen the understanding of non-drug-based approaches to managing seizures. Notably, LivaNova will unveil early findings from its significant real-world evidence study, referred to as “CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy.”
Commitment to Enhancing Quality of Life
In her statements, Stephanie Bolton, President of Global Epilepsy at LivaNova, expressed the company's commitment to enhancing access to healthcare and improving the lives of patients suffering from epilepsy globally. She emphasized that these poster presentations would convey valuable interim data from the CORE-VNS initiative, alongside other pertinent clinical research findings that underline LivaNova's dedication to advancing the field of epilepsy treatment.
Scientific Presentations and Opportunities
The American Epilepsy Society Annual Meeting will offer attendees a chance to browse through LivaNova's research posters on December 7 and 8, with featured presentations scheduled daily from noon to 2:00 p.m. PST. Additionally, LivaNova's scientific display will present an array of posters on December 9, further broadening the reach and impact of its research work.
Featured Studies on VNS Therapy
The agenda will include various engaging presentations such as:
- CORE-VNS: Dosing and Titration of VNS Therapy presented by Dr. Ryan Verner
- Long-Term Adjunctive VNS Therapy Use in Patients with Genetic Epilepsy presented by Dr. Nicola Specchio
- Long-term Experience of VNS Therapy in Children Under 18 presented by Dr. Muhammad Zafar
- Focal Onset Seizure Responses in Children at 24 Months showcased by Dr. James Wheless
- Exploratory Analysis of an fMRI-Guided Titration Paradigm for Microburst VNS Therapy presented by Dr. Ann Mertens
On December 8, the following presentations will also catch attention:
- Long-term Experience of VNS in Lennox-Gastaut Syndrome presented by Dr. Paul D. Lyons
- Long-Term Outcomes in Patients with Generalized Tonic-Clonic Seizures Following VNS Therapy presented by Dr. Ana Suller-Marti
Understanding VNS Therapy for Epilepsy
VNS Therapy is recognized for its clinical efficacy and safety as an adjunct treatment for individuals battling drug-resistant epilepsy, whether adult or pediatric patients aged four and above experiencing partial seizures. This innovative therapy is specifically intended to decrease seizure frequency and represents a valuable option for those unable to find relief through traditional antiepileptic medications, impacting approximately one-third of epilepsy patients.
Potential Complications and Patient Safety
The therapy also comes with certain risks, as the incidence of adverse effects in some patients may include voice alterations, increased coughing, and other manageable side effects. Surgical infection remains the most commonly observed complication associated with the implantation procedure. www.VNSTherapy.com provides crucial information regarding safety measures associated with the therapy.
About LivaNova
LivaNova PLC stands as a global leader in the medical technology field, armed with nearly fifty years of rich experience and a firm commitment to delivering state-of-the-art medical technologies. The company's mission focuses on providing hope to patients and their families dealing with neurological and cardiac issues. Based in London, LivaNova employs around 2,900 staff members and has established a significant presence in over 100 countries, dedicated to enhancing patient care for various healthcare systems around the globe.
Frequently Asked Questions
What is the purpose of LivaNova's participation in the AES 2024 Annual Meeting?
LivaNova aims to share its scientific findings and advancements in epilepsy treatment, particularly through VNS Therapy, to improve patient care and outcomes.
What is VNS Therapy?
VNS Therapy is a clinical treatment option that involves electrical stimulation of the vagus nerve to reduce seizure frequency in patients with drug-resistant epilepsy.
Where can attendees view LivaNova's research posters?
Research posters will be available for viewing during the AES Annual Meeting, specifically on December 7 and 8, with dedicated presentation slots from noon to 2:00 p.m. PST.
Who will present the studies at the AES Meeting?
Various researchers, including LivaNova employees and independent investigators, will present their findings and studies at the meeting.
What benefits does VNS Therapy offer?
VNS Therapy is designed to help individuals with drug-resistant epilepsy manage their seizures, improving overall quality of life for patients.
